SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 24, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed4mo ago
Insider cluster: 2 insiders, $14.1M total
Actionable Insight • Neutral

Insider sales post-merger announcement are common and not necessarily bearish, but monitor any unusual patterns or changes in deal sentiment. The merger agreement appears to be the main catalyst; focus on stockholder vote and regulatory clearances.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$132.68
T+0 close · Jun 24, 2026 · via day close
Latest settled
+1.19%
T+20 · $134.26
Vs SPY
+0.66%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jun 25 $132.68entry
  2. T+1 · 5mo ago −0.10%α +0.63% · $132.55
  3. T+5 · 5mo ago +0.07%α −1.49% · $132.77
  4. T+20 · 4mo ago +1.19%α +0.66% · $134.26
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top insiders (CEO and CMO) sold a total of $14.1M in open-market transactions on June 22, 2026, just days after the company announced a merger agreement with AbbVie. The sales represent 0.14% of market cap and are likely routine monetization ahead of the deal close, but the timing draws attention.

Key Financial Metrics

Direction
selling
Total Value
$14.1M
Insiders
2

Key Facts

  • CEO Michael Thomas Henderson sold 80,000 shares at $132.54 (~$10.6M) on June 22.
  • CMO Carl Dambkowski sold 26,400 shares at $132.60 (~$3.5M) on June 22.
  • Total insider sales of $14.1M represent 0.14% of APGE's $10B market cap.
  • Sales occurred 4 days after the June 18 merger agreement with AbbVie (via Andor entities).

Financial Impact

$14.1M in insider sales, representing 0.14% of market cap

insider ownershipshare float

Risk Factors

  • Additional insider sales could erode confidence in deal completion.
  • Regulatory or stockholder approval delays could affect timeline.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-APGE-1782345739974

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (10h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026